Femtobiomed, Inc.

As of December 31, 2025, Femtobiomed, Inc. carries a market capitalization of 24.50B, placing it among publicly traded companies globally. Its enterprise value stands at 24.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Femtobiomed, Inc. has 8.54M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 68.52, and the price-to-book ratio stands at -2.44.

These figures are as of December 31, 2025. The EV/Sales ratio of 69.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 24.75B versus a market cap of 24.50B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Femtobiomed, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -3.68, indicating conservative leverage, while an interest coverage ratio of -4.19 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -6.41, reflecting losses generated across the asset base. The company generates approximately 23.76M in revenue per employee across its workforce of 15.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.78 indicates how many times Femtobiomed, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on August 24, 2026, Femtobiomed, Inc.'s stock has declined approximately 99.21% over the past 52 weeks. The 50-day moving average sits at 1,035.74, while the 200-day moving average is 2,762.05.

Over the twelve months ended December 31, 2025, Femtobiomed, Inc. generated 356.39M in revenue and converted that into -144.98M in net income, yielding earnings per share of -17.04. EBITDA reached -2.96B, while operating income came in at -3.36B.

As of December 31, 2025, Femtobiomed, Inc. holds 120.76M in cash and equivalents against 369.14M in total debt, resulting in a net debt position of 138.29M. Total book value stands at -10.04B, with working capital of -10.40B providing operational flexibility.

Femtobiomed, Inc. produced -2.05B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -43.05M in capital expenditures, free cash flow totaled -2.09B - equivalent to -245.98 per share.

Over the twelve months ended December 31, 2025, Femtobiomed, Inc. posted a gross margin of 76.71, reflecting its pricing power and cost economics. The operating margin of -943.97 and net profit margin of -40.68 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -8.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.07, meaning Femtobiomed, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Femtobiomed, Inc.'s most recent stock split took place on July 22, 2021 with a 2:3 split ratio.

As of December 31, 2025, Femtobiomed, Inc. has an Altman Z-Score of -78.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.